Liver Cirrhosis Pipeline | Companies- CymaBay Therapeutics, Mirum Pharmaceuticals, Pharmicell Co., Ltd., Can-Fite BioPharma, Genfit, SHIONOGI & Co., COUR Pharmaceutical, Zydus Therapeutics Inc, Genkyotex SA, Gannex Pharma Co., Ltd., Novartis, and Others

DelveInsight's, "Liver Cirrhosis Pipeline Insight 2023" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Liver Cirrhosis pipeline landscape. It covers the Liver Cirrhosis pipeline drug profiles, including Liver Cirrhosis clinical trials and nonclinical stage products. It also covers the Liver Cirrhosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

To explore more information on the latest breakthroughs in the Liver Cirrhosis Pipeline treatment landscape of the report, click here @ Liver Cirrhosis Pipeline Outlook- https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key takeaways from the Liver Cirrhosis Pipeline Report
• Over 50+ Liver Cirrhosis companies are evaluating 50+ Liver Cirrhosis pipeline therapies in various stages of development, and their anticipated acceptance in the Liver Cirrhosis market would significantly increase market revenue.
• The leading Liver Cirrhosis Companies includes CymaBay Therapeutics, Mirum Pharmaceuticals, Pharmicell Co., Ltd., Can-Fite BioPharma, Genfit, SHIONOGI & Co., COUR Pharmaceutical, Zydus Therapeutics Inc, Genkyotex SA, Gannex Pharma Co., Ltd., Novartis, HighTide Biopharma Pty Ltd, Chia Tai Tianqing Pharmaceutical Group Co.Ltd., GlaxoSmithKline, Ohara Pharmaceutical, Pliant Therapeutics, MYR Pharmaceuticals, Active Biotech, Future Medicine Co Ltd., Dr. Falk Pharma GmbH, Suzhou Zelgen Biopharmaceuticals, and others.
• Promising Liver Cirrhosis Pipeline Therapies includes IDN-6556, ADSCs, NGM282, Rifaximin SSD 40 mg IR tablet, Livercellgram, INT-747, Obeticholic Acid (OCA), and others.
• The Liver Cirrhosis Companies and academics that are working to assess challenges and seek opportunities that could influence Liver Cirrhosis R&D. The Liver Cirrhosis pipeline therapies under development are focused on novel approaches to treat/improve the disease condition.
• Seladelpar (MBX-8025) is a potent, selective, orally active peroxisome proliferator-activated receptor δ (PPARδ) agonist in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC). It has received Breakthrough Therapy Designation (FDA) and PRIME status (EMEA); Orphan Drug Designation in U.S. and Europe. Backed by an extensive body of clinical evidence and global patient experience through its Phase 2 and Phase 3 (ENHANCE) studies of seladelpar in Primary Biliary Cholangitis (PBC).

For further information, refer to the detailed Liver Cirrhosis Unmet Needs, Liver Cirrhosis Market Drivers, and Liver Cirrhosis Market Barriers, click here for Liver Cirrhosis Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Liver Cirrhosis Overview
Liver cirrhosis refers to a shrunken, scarred and hardened liver with potential for deterioration of liver function. It results from chronic (long-term) damage to the liver from various causes, leading to progressive scarring of the liver over years. Liver cirrhosis is a serious condition because once the liver becomes cirrhotic, the damage to the liver is irreversible. Cirrhosis is classified as compensated or decompensated.

Request a sample and discover the recent advances in Liver Cirrhosis Ongoing Clinical Trial Analysis and Medications, click here @ Liver Cirrhosis Treatment Landscape- https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Liver Cirrhosis Emerging Drugs Profile
• Seladelpar: CymaBay Therapeutics
Seladelpar (MBX-8025) is a potent, selective, orally active peroxisome proliferator-activated receptor δ (PPARδ) agonist in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC). It has received Breakthrough Therapy Designation (FDA) and PRIME status (EMEA); Orphan Drug Designation in U.S. and Europe. Backed by an extensive body of clinical evidence and global patient experience through its Phase 2 and Phase 3 (ENHANCE) studies of seladelpar in Primary Biliary Cholangitis (PBC)
• Volixibat: Mirum Pharmaceuticals
Volixibat is a minimally absorbed, orally administered investigational therapy designed to selectively inhibit ileal bile acid transporter (IBAT), a protein that is primarily responsible for recycling bile acids from the intestine to the liver. We believe that volixibat may offer a novel approach in the treatment of rare liver diseases impacting both adults and children by blocking the recycling of bile acids, thereby reducing bile acids systemically. Volixibat is currently being studied in intrahepatic cholestasis of pregnancy, primary sclerosing cholangitis, and primary biliary cholangitis.

Dive deep into rich insights for drugs for Liver Cirrhosis Market Drivers and Liver Cirrhosis Market Barriers, click here @ Liver Cirrhosis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Liver Cirrhosis Pipeline Therapeutics Assessment
There are approx. 50+ key companies which are developing the therapies for Liver Cirrhosis. The companies which have their Liver Cirrhosis drug candidates in the most advanced stage, i.e. phase III include, CymaBay Therapeutics.

Scope of the Liver Cirrhosis Pipeline Report
• Coverage- Global
• Liver Cirrhosis Companies- CymaBay Therapeutics, Mirum Pharmaceuticals, Pharmicell Co., Ltd., Can-Fite BioPharma, Genfit, SHIONOGI & Co., COUR Pharmaceutical, Zydus Therapeutics Inc, Genkyotex SA, Gannex Pharma Co., Ltd., Novartis, HighTide Biopharma Pty Ltd, Chia Tai Tianqing Pharmaceutical Group Co.Ltd., GlaxoSmithKline, Ohara Pharmaceutical, Pliant Therapeutics, MYR Pharmaceuticals, Active Biotech, Future Medicine Co Ltd., Dr. Falk Pharma GmbH, Suzhou Zelgen Biopharmaceuticals, and others.
• Liver Cirrhosis Pipeline Therapies- IDN-6556, ADSCs, NGM282, Rifaximin SSD 40 mg IR tablet, Livercellgram, INT-747, Obeticholic Acid (OCA), and others.
• Liver Cirrhosis Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Liver Cirrhosis Mergers and acquisitions, Liver Cirrhosis Licensing Activities @ Liver Cirrhosis Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Liver Cirrhosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Liver Cirrhosis - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Seladelpar: CymaBay Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. AV 1142742: Active Biotech
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. ADR-001: Rohto Pharmaceutical
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. ZG 5216: Suzhou Zelgen Biopharmaceuticals
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Liver Cirrhosis Key Companies
21. Liver Cirrhosis Key Products
22. Liver Cirrhosis- Unmet Needs
23. Liver Cirrhosis- Market Drivers and Barriers
24. Liver Cirrhosis- Future Perspectives and Conclusion
25. Liver Cirrhosis Analyst Views
26. Liver Cirrhosis Key Companies
27. Appendix

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

This release was published on openPR.